Menu Search
Equities

Chongqing Genrix Biopharmaceutical Co Ltd

688443:SHH

Chongqing Genrix Biopharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)22.75
  • Today's Change-0.20 / -0.87%
  • Shares traded4.80m
  • 1 Year change-28.75%
  • Beta--
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Chongqing Genrix Biopharmaceutical Co Ltd had net income fall 39.03% from a loss of 576.37m to a larger loss of 801.32m despite a 154.92% increase in revenues from 475.24k to 1.21m.
Gross margin-214.22%
Net profit margin-71,021.27%
Operating margin-71,021.02%
Return on assets-20.89%
Return on equity-27.79%
Return on investment-21.71%
More ▼

Cash flow in CNYView more

In 2023, Chongqing Genrix Biopharmaceutical Co Ltd increased its cash reserves by 5,769.30%, or 2.84bn. Cash Flow from Financing totalled 3.10bn or 255,866.66% of revenues. In addition the company used 377.58m for operations while cash from investing totalled 120.62m.
Cash flow per share--
Price/Cash flow per share--
Book value per share6.81
Tangible book value per share6.70
More ▼

Balance sheet in CNYView more

Chongqing Genrix Biopharmaceutical Co Ltd appears to have little financial risk as the company holds a substantial amount of cash on its books. In fact, 0.35% of the market capitalization can be attributed to its 2.89bn and debt could be paid in full if management chose.
Current ratio20.50
Quick ratio20.06
Total debt/total equity0.2584
Total debt/total capital0.2053
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.